Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2009-2012

ABSTRACT

This study compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for 2 weeks in patients with Non-small Cell Lung Cancer (NSCLC) without epidermal growth factor receptor (EGFR) mutations. Expanded acronym : [P]aclitaxel/Ca[r]boplatin (PC) followed by Gef[i]tinib in A[d]vanc[e]d Non-small Cell Lung Cancer (NSCLC): Randomized phase II study. Detailed Description A randomized phase II trial that compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for 2 weeks in patients with NSCLC without EGFR mutations. While previous studies with cytotoxic agents and gefitinib failed to show any benefit, we altered the schedule of administration in hopes to gain synergy between agents. More... »

URL

https://clinicaltrials.gov/show/NCT01196234

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This study compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for 2 weeks in patients with Non-small Cell Lung Cancer (NSCLC) without epidermal growth factor receptor (EGFR) mutations. Expanded acronym : [P]aclitaxel/Ca[r]boplatin (PC) followed by Gef[i]tinib in A[d]vanc[e]d Non-small Cell Lung Cancer (NSCLC): Randomized phase II study.\n\nDetailed Description\nA randomized phase II trial that compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for 2 weeks in patients with NSCLC without EGFR mutations. While previous studies with cytotoxic agents and gefitinib failed to show any benefit, we altered the schedule of administration in hopes to gain synergy between agents.", 
    "endDate": "2012-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01196234", 
    "keywords": [
      "Non-Small-Cell Lung Carcinoma", 
      "Phase II study", 
      "gefitinib", 
      "patient", 
      "epidermal growth factor receptor", 
      "mutation", 
      "acronym", 
      "GEFs", 
      "randomized phase II trial", 
      "non small cell lung cancer", 
      "previous study", 
      "cytotoxic agent", 
      "benefit", 
      "Appointment and Schedule", 
      "Organization and Administration", 
      "synergy", 
      "agent"
    ], 
    "name": "Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01196234"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00009.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.418152.b", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413967.e", 
        "type": "Organization"
      }
    ], 
    "startDate": "2009-12-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/s12885-015-1714-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012104534", 
          "https://doi.org/10.1186/s12885-015-1714-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01196234"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01196234'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01196234'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01196234'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01196234'


 

This table displays all metadata directly associated to this object as RDF triples.

42 TRIPLES      16 PREDICATES      34 URIs      26 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01196234 schema:about anzsrc-for:3142
2 schema:description This study compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for 2 weeks in patients with Non-small Cell Lung Cancer (NSCLC) without epidermal growth factor receptor (EGFR) mutations. Expanded acronym : [P]aclitaxel/Ca[r]boplatin (PC) followed by Gef[i]tinib in A[d]vanc[e]d Non-small Cell Lung Cancer (NSCLC): Randomized phase II study. Detailed Description A randomized phase II trial that compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for 2 weeks in patients with NSCLC without EGFR mutations. While previous studies with cytotoxic agents and gefitinib failed to show any benefit, we altered the schedule of administration in hopes to gain synergy between agents.
3 schema:endDate 2012-12-01T00:00:00Z
4 schema:keywords Appointment and Schedule
5 GEFs
6 Non-Small-Cell Lung Carcinoma
7 Organization and Administration
8 Phase II study
9 acronym
10 agent
11 benefit
12 cytotoxic agent
13 epidermal growth factor receptor
14 gefitinib
15 mutation
16 non small cell lung cancer
17 patient
18 previous study
19 randomized phase II trial
20 synergy
21 schema:name Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study
22 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01196234
23 schema:sdDatePublished 2019-03-07T15:23
24 schema:sdLicense https://scigraph.springernature.com/explorer/license/
25 schema:sdPublisher N8a1ab816c59540b2af637c8169941bf2
26 schema:sponsor https://www.grid.ac/institutes/grid.413967.e
27 https://www.grid.ac/institutes/grid.418152.b
28 schema:startDate 2009-12-01T00:00:00Z
29 schema:subjectOf sg:pub.10.1186/s12885-015-1714-y
30 schema:url https://clinicaltrials.gov/show/NCT01196234
31 sgo:license sg:explorer/license/
32 sgo:sdDataset clinical_trials
33 rdf:type schema:MedicalStudy
34 N8a1ab816c59540b2af637c8169941bf2 schema:name Springer Nature - SN SciGraph project
35 rdf:type schema:Organization
36 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
37 rdf:type schema:DefinedTerm
38 sg:pub.10.1186/s12885-015-1714-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1012104534
39 https://doi.org/10.1186/s12885-015-1714-y
40 rdf:type schema:CreativeWork
41 https://www.grid.ac/institutes/grid.413967.e schema:Organization
42 https://www.grid.ac/institutes/grid.418152.b schema:Organization
 




Preview window. Press ESC to close (or click here)


...